MLYS Key Statistics, Chart & Performance
The current stock price of MLYS is 41.87 USD. In the past month the price increased by 4.94%. In the past year, price increased by 235.23%.
MLYS Latest News, Press Relases and Analysis
MLYS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About MLYS
Company Profile
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania and currently employs 51 full-time employees. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The company has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). The company is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.
Company Info
MINERALYS THERAPEUTICS INC
150 N. Radnor Chester Road, Suite F200
Radnor PENNSYLVANIA US
Employees: 51
Phone: 18883786240
MINERALYS THERAPEUTICS INC / MLYS FAQ
What does MLYS do?
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania and currently employs 51 full-time employees. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The company has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). The company is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.
Can you provide the latest stock price for MINERALYS THERAPEUTICS INC?
The current stock price of MLYS is 41.87 USD.
What is the dividend status of MINERALYS THERAPEUTICS INC?
MLYS does not pay a dividend.
What is the ChartMill technical and fundamental rating of MLYS stock?
MLYS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for MINERALYS THERAPEUTICS INC?
MINERALYS THERAPEUTICS INC (MLYS) operates in the Health Care sector and the Biotechnology industry.
Should I buy MLYS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MLYS.
MLYS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MLYS. When comparing the yearly performance of all stocks, MLYS is one of the better performing stocks in the market, outperforming 99.15% of all stocks.
MLYS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MLYS. While MLYS has a great health rating, there are worries on its profitability.
MLYS Financial Highlights
Over the last trailing twelve months MLYS reported a non-GAAP Earnings per Share(EPS) of -2.95. The EPS increased by 9.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.56% | ||
| ROE | -29.73% | ||
| Debt/Equity | 0 |
MLYS Forecast & Estimates
15 analysts have analysed MLYS and the average price target is 46.79 USD. This implies a price increase of 11.76% is expected in the next year compared to the current price of 41.87.